You are here: Industry Insights > favipiravir

News List

Indoco launches favipiravir 400 mg tablets expresspharma
September 28, 2020
Fevindo - 400 will be made available at all government approved COVID care centres and selected medical practitioners across the country.
BDR Pharma to launch 400 mg Favipiravir tablets expresspharma
September 07, 2020
BDR Pharmaceuticals said it plans to launch 400 mg Favipiravir tablets, used for treating COVID-19 patients, in the country.
FDC launches two favipiravir variants for COVID-19 treatment expresspharma
August 26, 2020
FDC announced the launch of two variants of favipiravir – PiFLU and Favenza – which will be used to treat mild to moderate cases of COVID-19 in India.
Dr Reddy’s Laboratories launches AVIGAN (favipiravir) in India expresspharma
August 20, 2020
Dr Reddy’s Laboratories announced the launch of AVIGAN (favipiravir) 200 mg tablets in India.
Fusion Health Care launches favipiravir for COVID-19 treatment expresspharma
August 18, 2020
Fusion Health Care, a pharma company based at Hyderabad, has announced the launch of its favipiravir drug under the brand name XARAVIR, for the treatment of mild to moderate COVID-19 cases.
Lee Pharma to launch favipiravir under brand name Faravir at Rs 27 per tablet expresspharma
August 17, 2020
Hyderabad-based, Lee Pharma has received DCGI’s approval for manufacturing and marketing of active pharmaceutical ingredients (API) for favipiravir in India.
MSN Laboratories to launch favipiravir at Rs 33 expresspharma
August 14, 2020
The company will be launching it on August 15 under the brand name Favilow.
FDA clears Appili Therapeutics to expand its trial of favipiravir for prrevention of Covid-19 pharmaceutical-business-review
August 13, 2020
Appili Therapeutics, a biopharmaceutical company focused on anti-infective drug development, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company clearance to proceed after Appili’s filing of ...
Prices of remdesivir and favipiravir being monitored in India, says report europeanpharmaceuticalreview
August 10, 2020
Regulatory bodies in India are tracking the cost of remdesivir and favipiravir amid the COVID-19 pandemic but should consider price caps, a report has suggested.
Zenara Pharma, a Biophore subsidiary, gets DCGI nod for favipiravir tablets expresspharma
August 06, 2020
The company informed that these tablets, to be marketed under brand name Favizen, will be manufactured with in-house API.

Previous page 1 2 3 4 5 6 Next page